ストックスクリーナーアプリを入手
5.00
2.04%
0.10
前日終値:
$4.90
開ける：
$4.87
24時間の取引高:
480.86K
Relative Volume:
1.64
時価総額：
$180.08M
収益：
-
当期純損益:
$-34.55M
株価収益率:
-4.5273
EPS:
-1.1044
ネットキャッシュフロー:
$-31.28M
1週間 パフォーマンス:
+12.36%
1か月 パフォーマンス:
+11.61%
6か月 パフォーマンス:
+338.60%
1年 パフォーマンス:
+354.55%
1日の値動き範囲:
$4.80
$5.06
1週間の範囲:
$4.085
$5.08
52週間の値動き範囲:
$1.00
$6.9099
An 2 Therapeutics Inc Stock (ANTX) Company Profile
名前
An 2 Therapeutics Inc
セクター
電話
(650) 331-9090
住所
1300 EL CAMINO REAL, SUITE 100, MENLO PARK
Compare ANTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
5.00 | 180.08M | 0 | -34.55M | -31.28M | -1.1044 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2024-08-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-12 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-01-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
すべてを表示
An 2 Therapeutics Inc (ANTX) 最新ニュース
Allarity Therapeutics to Present Trial-in-Progress Poster - GlobeNewswire
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - PR Newswire
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P - GlobeNewswire
Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise - StocksToTrade
TGTX Stock Surges As Briumvi Pipeline Momentum Accelerates - StocksToTrade
Tango Therapeutics Announces Combination of Vopimetostat - GlobeNewswire
Autobahn Therapeutics Reports Positive Phase 2 Topline Data for Elunetirom in Bipolar Depression, Demonstrating Rapid, Robust, and Durable Antidepressant Effects - Business Wire
Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Business Wire
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - Business Wire
Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting - Business Wire
Monopar Therapeutics Presents Phase 2 Data for ALXN1840 at EASL Congress 2026, Demonstrating Liver Disease Stabilization and Neurological Improvements in Wilson Disease Patients - Quiver Quantitative
Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease - PR Newswire
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline - PR Newswire
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic DermatitisSlideshow (NASDAQ:APGE) 2026-05-30 - Seeking Alpha
Monopar Therapeutics (MNPR) shares Phase 2 Wilson disease data at EASL 2026 - Stock Titan
C4 Therapeutics, Inc. unveils Phase 2 trial progress for cemsidomide at ASCO26 - Traders Union
Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout - PR Newswire
This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday - Benzinga
Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting - BioSpace
Black Diamond Therapeutics Announces Positive Phase 2 - GlobeNewswire
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - Business Wire
Relay Therapeutics (Nasdaq: RLAY) shares early zovegalisib vascular anomaly data - Stock Titan
Amplexd Therapeutics Initiates Phase 2 Clinical Trial of Investigational EGCg-Based HPV Therapy - GlobeNewswire
UPDATEQuince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - GlobeNewswire
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVCSlideshow (NASDAQ:TNYA) 2026-05-17 - Seeking Alpha
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology - Yahoo Finance
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $26, Implies 2% Upside - TradingView
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center - GlobeNewswire
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 - PR Newswire
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-05-09 - Seeking Alpha
Millennium-linked entities file 13G/A for Tenax Therapeutics (NASDAQ: TENX) reporting ~2% stakes - Stock Titan
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease - GlobeNewswire
Avalo Therapeutics (AVTX) jumps as Phase 2 LOTUS topline results and $375M financing reshape outlook - Quiver Quantitative
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease - Business Wire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas - Yahoo Finance
MapLight Therapeutics Completes Enrollment in ZEPHYR Phase 2 Trial for Schizophrenia and Final Patient Visit in IRIS Phase 2 Trial for Autism Spectrum Disorder - Quiver Quantitative
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with - GlobeNewswire
Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study - Yahoo Finance
Rein's lung-scarring trial reaches 8 patients, expands to 3 countries - Stock Titan
Tenaya Therapeutics Announces Late-Breaking Oral - GlobeNewswire
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer - Investing News Network
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier - Yahoo Finance
Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268 - BioSpace
Convergent Therapeutics to Present Phase 2 Data for CONV01-α in Lu-PSMA pretreated Metastatic Castration-Resistant Prostate Cancer Patients at the 2026 ASCO Annual Meeting - BioSpace
Spotlighting Abeona Therapeutics And 2 More High Growth Stocks Insiders Favor - Yahoo Finance
Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting - Business Wire
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - GlobeNewswire
Black Diamond Therapeutics Announces Oral Presentation of - GlobeNewswire
Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program - Yahoo Finance
ZEVRA THERAPEUTICS, INC. ($ZVRA) CEO 2025 Pay Revealed - Quiver Quantitative
Sapience Therapeutics Presents First Clinical Results from Phase 2 Study of ST316, First-in-Class β-catenin Antagonist, in Second-Line Colorectal Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2026 - PR Newswire
An 2 Therapeutics Inc (ANTX) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):